GelStat Corp. reported revenue results for the second quarter ended June 30, 2014. For the quarter, the company reported revenue of $14,038, up 261% against $3,880 over the same period in 2013 and up 136% from $5,942 in the first quarter of 2014. The revenue growth was attributable to increasing sales of GelStat Migraine primarily driven by small advertising tests designed to drive new customer acquisitions. While the revenue numbers themselves are insignificant, the trends and validation of marketing efforts are very meaningful.

The company forecasts revenue of $400,000 for the third quarter and $500,000 for the fourth quarter of 2014.